NKore BioTherapeutics

NKore BioTherapeutics is a pre-clinical stage biotechnology company dedicated to developing next-generation, off-the-shelf Natural Killer (NK) cell therapies for the treatment of solid tumors. The company's primary focus is on engineering CAR-NK cells that specifically target Glypican-3 (GPC3), a protein highly expressed in hepatocellular carcinoma and other difficult-to-treat cancers. By leveraging advanced cell engineering techniques, NKore aims to overcome the limitations of current immunotherapies in the solid tumor microenvironment. The company is headquartered in San Diego and operates within the JLABS life science incubator ecosystem. Its approach seeks to provide a more accessible and potent alternative to patient-derived T-cell therapies.